Literature DB >> 11690609

The neuropsychological basis of addictive behaviour.

B J Everitt1, A Dickinson, T W Robbins.   

Abstract

The argument advanced in this review is that drug addiction can be understood in terms of normal learning and memory systems of the brain which, through the actions of chronically self-administered drugs, are pathologically subverted, thereby leading to the establishment of compulsive drug-seeking habits, strengthened by the motivational impact of drug-associated stimuli and occurring at the expense of other sources of reinforcement. We review data from our studies that have utilized procedures which reveal the various influences of pavlovian stimuli on goal-directed behaviour, namely discriminated approach, pavlovian-to-instrumental transfer and conditioned reinforcement, in order to demonstrate their overlapping and also unique neural bases. These fundamental studies are also reviewed in the context of the neural and psychological mechanisms underlying drug-seeking behaviour that is under the control of drug-associated environmental stimuli. The ways in which such drug-seeking behaviour becomes compulsive and habitual, as well as the propensity for relapse to drug-seeking even after long periods of relapse, are discussed in terms of the aberrant learning set in train by the effects of self-administered drugs on plastic processes in limbic cortical-ventral striatal systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11690609     DOI: 10.1016/s0165-0173(01)00088-1

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  257 in total

Review 1.  The neuroscience of natural rewards: relevance to addictive drugs.

Authors:  Ann E Kelley; Kent C Berridge
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

Review 2.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

3.  Inactivation of the central nucleus of the amygdala reduces the effect of punishment on cocaine self-administration in rats.

Authors:  YueQiang Xue; Jeffery D Steketee; WenLin Sun
Journal:  Eur J Neurosci       Date:  2012-02-06       Impact factor: 3.386

Review 4.  Motivational Processes Underlying Substance Abuse Disorder.

Authors:  Paul J Meyer; Christopher P King; Carrie R Ferrario
Journal:  Curr Top Behav Neurosci       Date:  2016

5.  Norepinephrine in prelimbic cortex delays extinction of amphetamine-induced conditioned place preference.

Authors:  Emanuele Claudio Latagliata; Pamela Saccoccio; Chiara Milia; Stefano Puglisi-Allegra
Journal:  Psychopharmacology (Berl)       Date:  2015-12-12       Impact factor: 4.530

6.  A classically conditioned cocaine cue acquires greater control over motivated behavior in rats prone to attribute incentive salience to a food cue.

Authors:  Lindsay M Yager; Terry E Robinson
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

7.  Tonic inhibition of accumbal spiny neurons by extrasynaptic α4βδ GABAA receptors modulates the actions of psychostimulants.

Authors:  Edward P Maguire; Tom Macpherson; Jerome D Swinny; Claire I Dixon; Murray B Herd; Delia Belelli; David N Stephens; Sarah L King; Jeremy J Lambert
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

8.  Conditioning processes contribute to severity of naloxone-precipitated withdrawal from acute opioid dependence.

Authors:  Gery Schulteis; Andrew C Morse; Jian Liu
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

9.  [Excessive compulsive buying or "behavioral addiction"? A case study].

Authors:  Sabine M Grüsser; Carolin Thalemann; Ulrike Albrecht
Journal:  Wien Klin Wochenschr       Date:  2004-03-31       Impact factor: 1.704

Review 10.  The debate over dopamine's role in reward: the case for incentive salience.

Authors:  Kent C Berridge
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.